Torqur AG, subsidiary of Swiss Rockets incubator and a clinical-stage company advancing targeted therapies in oncodermatology and oncology, announced the...
Industry report measures progress in six main areas: supply chain resilience, talent pool, R&D ecosystem, manufacturing agility, government polic...
CRYPTICS study met the primary efficacy endpoint measure, 24-hour chest tube drainage (Difference in LS Means was 142.0 mL; 95.576% confidence interval...
New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with advanced workflows and long-term value Philips deb...
Pierre Boulud, Chief Executive Officer of bioMérieux, set the tone for the company’s first-half 2025 performance: “With a stron...
NPI-001 shows more than 50% reduction in photoreceptor loss caused by RP associated with USH over two years NPI-001 was well tolerated, with no persiste...
-Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Best-in-Class PTRS, announced results from the landmark myCare-040 clinical ...
Corner Therapeutics, an in vivo T cell modulation and immunotherapy company pioneering novel approaches to cancer and infection, published research in mB...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to th...
Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 2...
New Jersey at a Glance – Often dubbed the “Medicine Chest of the World,” New Jersey has a rich legacy and a dynamic present as a global h...
Valneva SE , a specialty vaccine company, announced that the United States Food and Drug Administration (FDA) has suspended the license for IX...
A collaborative research team led by Hong Kong Baptist University (HKBU) has developed a multifunctional nanorobot equipped with silver and gold nanorods...
Engagement with FDA on GH001 IND complete response ongoing The fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months...
© 2025 Biopharma Boardroom. All Rights Reserved.
